Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing R...
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: GlobeNewswire
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details: Poster Title:Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter:Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational SciencesSession:Poster Session 1; Vancouver Island RoomDate/Time:Monday, April 13, 2026, at 7:30 PM PTLocation:Fairmont Hote
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswire
- Sagimet Biosciences (SGMT) is now covered by Rodman & Renshaw. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
- Sagimet Biosciences (SGMT) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sellMarketBeat
- Sagimet Biosciences (SGMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
SGMT
Earnings
- 3/11/26 - Beat
SGMT
Sec Filings
- 4/21/26 - Form ARS
- 4/21/26 - Form DEF
- 4/21/26 - Form 8-K
- SGMT's page on the SEC website